Back to Search Start Over

Effects of Vildagliptin and Metformin on Blood Pressure and Heart Rate Responses to Small Intestinal Glucose in Type 2 Diabetes.

Authors :
Tongzhi Wu
Trahair, Laurence G.
Little, Tanya J.
Bound, Michelle J.
Xiang Zhang
Hang Wu
Zilin Sun
Horowitz, Michael
Rayner, Christopher K.
Jones, Karen L.
Wu, Tongzhi
Zhang, Xiang
Wu, Hang
Sun, Zilin
Source :
Diabetes Care; May2017, Vol. 40 Issue 5, p702-705, 4p, 1 Graph
Publication Year :
2017

Abstract

<bold>Objective: </bold>To evaluate effects of vildagliptin and metformin on blood pressure (BP) and heart rate (HR) responses to intraduodenal (ID) glucose in diet-controlled type 2 diabetes.<bold>Research Design and Methods: </bold>Study A compared vildagliptin (50 mg) and placebo, given 60 min before a 120-min ID glucose infusion at 2 or 4 kcal/min (ID2 or ID4) in 16 patients. Study B compared metformin (850 mg) and placebo, given 30 min before ID2 over 120 min in 9 patients.<bold>Results: </bold>Systolic (P = 0.002) and diastolic (P < 0.001) BP were lower and HR greater (P = 0.005) after vildagliptin compared with placebo, without interaction between vildagliptin and the glucose infusion rate. In contrast, HR was greater after metformin than placebo (P < 0.001), without any difference in systolic or diastolic BP.<bold>Conclusions: </bold>Vildagliptin reduces BP and increases HR, whereas metformin increases HR without affecting BP during ID glucose infusion in type 2 diabetes. These distinct cardiovascular profiles during enteral nutrient exposure may have implications for postprandial hypotension. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01495992
Volume :
40
Issue :
5
Database :
Complementary Index
Journal :
Diabetes Care
Publication Type :
Academic Journal
Accession number :
122615300
Full Text :
https://doi.org/10.2337/dc16-2391